Physician doubts and counselling shortages threaten impact of profiling on pharma
This article was originally published in Scrip
A large prospective survey of the psychological impacts of genetic testing – the largest ever such study by a factor of 10 – suggests that anxiety about insights to their medical future is not a factor that is likely to delay the advent of widespread testing. Indeed, it seems more likely that a shortage of genetic counsellors and the discomfort of primary care physicians will hold back the field. And for the pharmaceutical industry, genetic profiling alongside advice from pharmacists to patients is likely to play a key role in facilitating pharmacogenomics-led drug choices that create greater compliance in the use of medicines to treat chronic conditions.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.